Average Co-Inventor Count = 6.57
ph-index = 11
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Protagonist Therapeutics, Inc. (18 from 32 patents)
2. Janssen Biotech, Inc. (1 from 410 patents)
3. The University of Queensland (1 from 340 patents)
4. Protaganist Therapeutics, Inc. (1 from 1 patent)
20 patents:
1. 12269856 - Hepcidin analogues and uses thereof
2. 12234300 - Conjugated hepcidin mimetics
3. 11884748 - Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
4. 11845808 - Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
5. 11807674 - Hepcidin analogues and uses thereof
6. 11753443 - Conjugated hepcidin mimetics
7. 11472842 - Analogues of hepcidin mimetics with improved in vivo half lives
8. 10941183 - Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
9. 10787490 - Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
10. 10729676 - Opioid agonist peptides and uses thereof
11. 10501515 - Hepcidin analogues and uses thereof
12. 10442846 - Hepcidin analogues and uses thereof
13. 10278957 - Opioid agonist peptides and uses thereof
14. 10196424 - Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
15. 10035824 - Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases